335 related articles for article (PubMed ID: 18316043)
1. Fragment-based activity space: smaller is better.
Hesterkamp T; Whittaker M
Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
[TBL] [Abstract][Full Text] [Related]
2. Fragonomics: fragment-based drug discovery.
Zartler ER; Shapiro MJ
Curr Opin Chem Biol; 2005 Aug; 9(4):366-70. PubMed ID: 15925537
[TBL] [Abstract][Full Text] [Related]
3. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
Jhoti H; Cleasby A; Verdonk M; Williams G
Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
[TBL] [Abstract][Full Text] [Related]
4. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided fragment screening for lead discovery.
Verdonk ML; Hartshorn MJ
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
[TBL] [Abstract][Full Text] [Related]
6. High throughput solubility determination with application to selection of compounds for fragment screening.
Colclough N; Hunter A; Kenny PW; Kittlety RS; Lobedan L; Tam KY; Timms MA
Bioorg Med Chem; 2008 Jul; 16(13):6611-6. PubMed ID: 18502135
[TBL] [Abstract][Full Text] [Related]
7. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
8. Design of screening collections for successful fragment-based lead discovery.
Na J; Hu Q
Methods Mol Biol; 2011; 685():219-40. PubMed ID: 20981526
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based lead discovery: a chemical update.
Erlanson DA
Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
Tsao DH; Sutherland AG; Jennings LD; Li Y; Rush TS; Alvarez JC; Ding W; Dushin EG; Dushin RG; Haney SA; Kenny CH; Malakian AK; Nilakantan R; Mosyak L
Bioorg Med Chem; 2006 Dec; 14(23):7953-61. PubMed ID: 16919463
[TBL] [Abstract][Full Text] [Related]
11. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.
Gill A; Cleasby A; Jhoti H
Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598
[TBL] [Abstract][Full Text] [Related]
12. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
13. High-throughput X-ray crystallography for drug discovery.
Blundell TL; Patel S
Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based drug design.
Feyfant E; Cross JB; Paris K; Tsao DH
Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based ligand discovery.
Fischer M; Hubbard RE
Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
[TBL] [Abstract][Full Text] [Related]
16. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
Rishton GM
Curr Opin Chem Biol; 2008 Jun; 12(3):340-51. PubMed ID: 18328272
[TBL] [Abstract][Full Text] [Related]
17. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods.
Lundqvist T
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):513-9. PubMed ID: 16022188
[TBL] [Abstract][Full Text] [Related]
18. A novel in silico approach to drug discovery via computational intelligence.
Hecht D; Fogel GB
J Chem Inf Model; 2009 Apr; 49(4):1105-21. PubMed ID: 19348414
[TBL] [Abstract][Full Text] [Related]
19. Selection criteria for drug-like compounds.
Muegge I
Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
[TBL] [Abstract][Full Text] [Related]
20. Lead generation and examples opinion regarding how to follow up hits.
Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
